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PSONET is an international network of independent 
partners that aims to document “real-life” use of sys-
temic drugs for psoriasis in different countries (1–3). 
Differences in how the registries’ populations are treated 
have implications for the analysis of data (as these fac-
tors could act as confounders for risk estimates), for the 
generalizability of results from individual registries, and 
for understanding dermatologist behaviour in different 
healthcare systems and countries. 
The objective of this study is to describe and compare 
the characteristics of patients treated with classic and 
biological agents for psoriasis in participating registries.
METHODS 
The study population are patients with moderate-to-severe psoria-
sis, over 18 years of age, who have received systemic treatment 
for psoriasis. Except for Clalit Health Services, which utilizes 
administrative data, participating registries are cohort studies that 
enrol patients when they first receive, or are currently receiving, 
a study drug. 
Baseline data from 7 countries’ registries included the Nether-
lands (Academic Medical Centre (AMC) psoriasis registry) (4, 
5), Australia (Australasian Psoriasis Registry), Spain (BIOBA-
DADERM) (6, 7), Israel (The Clalit Health Services), Denmark 
(DERMBIO) (8, 9), Germany (PSOBEST) (10) and Italy (PSO-
CARE) (11, 12). 
Participating registries provided aggregated summary data 
concerning baseline, demographic and disease characteristics of 
their cohort. Table SI1 gives information about the organization of 
each registry. Inclusion criteria for the different registers are earlier 
described in (3). In general, they include all biological treatments 
consecutively and a convenience sampling of classic drugs. All 
registries received approval from their local ethics committee, 
and comply with the principles of the Declaration of Helsinki.
Statistical analysis
Pooled analyses were performed using Stata 12.1 software (Sta-
taCorp College Station, TX, USA). To measure the association 
between exposure to biologics or classic systemic therapies and 
a priori defined variables, differences in means between groups 
were used for continuous variables, and odds ratios (OR) for ca-
tegorical variables. To pool data from registries, forest plots were 
used and a random-effects meta-analysis was conducted to describe 
differences among groups exposed to biologics or conventional 
therapies. Pooled estimates of effects were produced if results 
were not too heterogeneous (I2 < 60%). Some registries were not 
able to provide data on all of the defined variables. Due to the lack 
of enrolment of patients receiving classic systemic therapy, AMC 
psoriasis registry data were not included in the forest plots and in 
comparisons of exposure cohorts. In all the other registries, if a 
patient began in the non-biological therapy group and subsequently 
received a biologic drug, his or her characteristics contributed to 
both groups in the analysis.
RESULTS
From the start of each registry to August 2012, a total 
of 20,232 patients had been enrolled in the registries 
and provided baseline information. This included 9,668 
(47.8%) initially treated with biologics and 10,564 
(52.2%) starting classic systemic therapies.
Demographic and disease characteristics are summa-
rized in Tables SII and SIII1. 
Some differences between patients receiving biologics 
and those receiving classic drugs were homogeneous 
between registries (I2 ≤ 60%). These are presented in 
forest plots in Fig. 1, which includes I2 values, and poo-
led estimates. Overall, patients on biologics were 0.42 
units of body mass index (BMI) heavier than those on 
classic systemic drugs (95% CI: 0.25–0.58). The OR of 
males vs. females receiving biologics was 1.08 (95% CI: 
0.94–1.24). Use of biologics was slightly less likely in 
current smokers (OR 0.89, 95% CI: 0.80–0.99). 
Fig. S11 shows the results in each registry, but not 
pooled estimates, because heterogeneity was too high 
(I2 > 60%). Age at entry, age at diagnosis and Psoriasis 
Area and Severity Index (PASI) at entry were too hete-
rogeneous among registries to be combined in the meta-
analysis. Italian and Spanish patients on biologics had a 
PASI significantly higher at entry and were significantly 
younger at diagnosis than those receiving classic syste-
mic therapies. Few registries reported measurements of 
body surface area (BSA) and Dermatology Life Quality 
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Index (DLQI) or SKINDEX, making comparisons bet-
ween registries difficult. 
Patients with psoriatic arthritis or nail disease were 
more likely to receive biologics than classic therapies in 
almost all registries, but the results were heterogeneous 
despite the significant OR favouring the usage of biologics 
in most of them. In registries from Italy and Spain, pa-
tients with psoriasis different from plaque psoriasis were 
significantly more likely to receive conventional drugs. 
DISCUSSION
In agreement with the findings of a previous PSO-
NET analysis (1), the current study revealed that wide 
between-country heterogeneity exists in the distribution 
of covariates potentially influencing treatment selec-
tion (e.g. age, PASI and proportion with non-chronic 
plaque psoriasis). Beyond between registry variability, 
the current study found that some covariates are related 
per se with the odds of receiving a biologic or a classic 
treatment in most registries, e.g. BMI, psoriatic arthritis, 
nail disease or proportion of current smokers. 
The strengths of this study are the increased power 
obtained from multiple registries compared with using 
each separately, the ability to describe and quantify 
between-country differences, and the use of a meta-
analytical approach, in which each registry acts as its 
own control, which limits the risk of biases related to 
differences between registries. In addition, meta-analysis 
is a good way to define and quantify heterogeneity and 
to balance out differences in sizes among the registries. 
Study limitations are: missing data from some regist-
ries, missing data on some predefined variables and that 
only univariate analysis was performed and we could not 
rule out that the factors we found as being associated with 
treatment choices were, in fact, intercorrelated and not 
independently associated with the treatment selection. A 
further limitation is that we could only analyse commonly 
measured and coded variables. Finally, the data were not 
updated. This delay is due to the extreme difficulty in 
combining data from different national registries. But 
because of the already high number of participants, we 
consider that this should not affect the results and overall 
conclusions. 
Methodological differences might explain some of 
the differences found. This is probably the case for 
the heterogeneity of the percentage of patients with 
psoriatic arthritis or in PASI values. PASI values are 
also influenced by the lack of wash-out periods before 
starting a new therapy (leading to variability and PASI 
decrease) in real-world registries and by the fact that 
a minimum PASI is mandatory to prescribe biologics 
in some countries (possibly leading to a factitious in-
crease). Single outlying results may also hide otherwise 
homogenous effects, e.g. only in the Danish registry is 
there no greatly increased use of biologics for psoriasis 
arthritis; thus, the otherwise highly significant prediction 
by psoriasis arthritis disappears.
Conclusion
Knowledge of the factors related to drug selection is 
important in order to plan statistical analysis of observa-
tional data (13). Each registry could use this information 
to develop strategies for dealing with prescription bias, 
using methods such as propensity scores (14). Identifi-
cation of differences in the international usage of drugs 
can be useful for interpretation of observational studies 
(e.g. generalization of results) (15), adds knowledge and 
understanding of different healthcare systems and might 
indicate areas for improvement in patient management. 
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Fig. 1. Forest plot showing the overall result in psoriasis 
characteristics of patients without substantial heterogeneity 
(I2<60%) in both biologic and control group among different 
registries: (a) differences in body mass index (BMI) between biologic 
and conventional treatment groups. (b) Odds ratio (OR) of biologic use 
compared with conventional treatment among current smokers. (c) OR 
of biologic use compared with conventional treatment among current 
drinkers.
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